FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
By understanding these mechanisms, you can better appreciate why the food choices you make are so important when using semaglutide for lasting results
Semaglutide GLP-1 Weight Loss Injections in Wesley Chapel, FL Neuvo Medical Spa offers Semaglutide GLP-1 weight loss injections to support your weight loss journey in Wesley Chapel, FL
Semaglutide (Subcutaneous Route) Mayo Clinic (2024)
The five-day threshold represents a balance between maintaining therapeutic levels and preventing excessive accumulation of the medication in your system
